Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
- Citation:
- Nat Commun vol 14
- Year:
- 2023
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- 3618
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233337, UG1CA233373
- Corr. Author:
- Authors:
- Mattia Rediti Aranzazu Fernandez-Martinez David Venet Françoise Rothé Katherine A. Hoadley Joel S. Parker Baljit Singh Jordan D. Campbell Karla V. Ballman David W. Hillman Eric P. Winer Sarra El-Abed Martine Piccart Serena Di Cosimo William Fraser Symmans Ian E. Krop Roberto Salgado Sherene Loi Lajos Pusztai Charles M. Perou Lisa A. Carey Christos Sotiriou
- Networks:
- LAPS-CT018, LAPS-NC007, LAPS-TX035
- Study
- Alliance-A152117
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-40601
- Phases:
- N/A, 3
- Keywords:
- Prognostic markers, Breast cancer, Tumour immunology